A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application

Qian Zhang; Lei Ding; Tianren Zhou; Qidi Zhai; Chenbo Ni; Chao Liang; Jie Li

doi:10.3389/fonc.2022.982426

A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application

Front Oncol. 2022 Sep 13:12:982426. doi: 10.3389/fonc.2022.982426. eCollection 2022.

Authors

Qian Zhang¹, Lei Ding¹, Tianren Zhou¹, Qidi Zhai¹, Chenbo Ni¹, Chao Liang¹, Jie Li¹

Affiliation

¹ Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Metabolic reprogramming is one of the characteristics of clear cell renal cell carcinoma (ccRCC). Although some treatments associated with the metabolic reprogramming for ccRCC have been identified, remain still lacking. In this study, we identified the differentially expressed genes (DEGs) associated with clinical traits with a total of 965 samples via DEG analysis and weighted correlation network analysis (WGCNA), screened the prognostic metabolism-related genes, and constructed the risk score prognostic models. We took the intersection of DEGs with significant difference coexpression modules and received two groups of intersection genes that were connected with metabolism via functional enrichment analysis. Then we respectively screened prognostic metabolic-related genes from the genes of the two intersection groups and constructed the risk score prognostic models. Compared with the predicted effect of clinical grade and stage for ccRCC patients, finally, we selected the model constructed with genes of ABAT, ALDH6A1, CHDH, EPHX2, ETNK2, and FBP1. The risk scores of the prognostic model were significantly related to overall survival (OS) and could serve as an independent prognostic factor. The Kaplan-Meier analysis and ROC curves revealed that the model efficiently predicts prognosis in the TCGA-KIRC cohort and the validation cohort. Then we investigated the potential underlying mechanism and sensitive drugs between high- and low-risk groups. The six key genes were significantly linked with worse OS and were downregulated in ccRCC, we confirmed the results in clinical samples. These results demonstrated the efficacy and robustness of the risk score prognostic model, based on the characteristics of metabolic reprogramming in ccRCC, and the key genes used in constructing the model also could develop into targets of molecular therapy for ccRCC.

Keywords: clear cell renal cell carcinoma; key gene; metabolic reprogramming; prognostic model; weighted correlation network analysis.